Lab­Corp nabs Chiltern, boost­ing its big Co­v­ance CRO group to 20K-plus staffers in $1.2B deal

Lab­Corp is go­ing deep in­to the CRO busi­ness.

A lit­tle more than two years af­ter pay­ing $6.1 bil­lion for Co­v­ance, Lab­Corp has now fol­lowed up with a $1.2 bil­lion cash deal for Chiltern, adding an­oth­er 4,500 clin­i­cal out­sourc­ing work­ers around the globe to its em­ploy­ee ros­ter.

The Chiltern ac­qui­si­tion is de­signed to get Lab­Corp deep­er in­to new and mid-sized bio­phar­mas. Its Co­v­ance group was al­ready a top-10 play­er when Lab­Corp stepped in with its deal. In a state­ment, the com­pa­ny not­ed it has han­dled more than 1,800 clin­i­cal tri­als over the past 5 years for clients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER